Seelos Therapeutics, Inc. – NASDAQ:SEEL
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Seelos Therapeutics stock price monthly change
-40.41%
month
Seelos Therapeutics stock price quarterly change
+8.55%
quarter
Seelos Therapeutics stock price yearly change
-48.32%
year
Seelos Therapeutics key metrics
Market Cap | 214.97K |
Enterprise value | 98.17M |
P/E | -1.22 |
EV/Sales | N/A |
EV/EBITDA | -1.34 |
Price/Sales | N/A |
Price/Book | -8.81 |
PEG ratio | -0.01 |
EPS | -5.14 |
Revenue | 1.97M |
EBITDA | -37.49M |
Income | -27.11M |
Revenue Q/Q | -28.34% |
Revenue Y/Y | 144.30% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1899.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSeelos Therapeutics stock price history
Seelos Therapeutics stock forecast
Seelos Therapeutics financial statements
| Jun 2023 | 336K | -29.49M | -8778.57% |
|---|---|---|---|
| Sep 2023 | 406K | 10.49M | 2585.71% |
| Dec 2023 | 653K | -5.45M | -835.07% |
| Mar 2024 | 579K | -2.66M | -460.1% |
| 2027 | 144.9M | 0 |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-11-10 | -0.1 | -0.18 |
|---|---|---|
| 2023-03-10 | -0.22231 | -0.17 |
| Jun 2023 | 11889000 | 59.06M | 496.84% |
|---|---|---|---|
| Sep 2023 | 6218000 | 36.63M | 589.1% |
| Dec 2023 | 5418000 | 38.92M | 718.49% |
| Mar 2024 | 3612000 | 36.71M | 1016.5% |
| Jun 2023 | -5.90M | 0 | -2.31M |
|---|---|---|---|
| Sep 2023 | -5.74M | 0 | 2.49M |
| Dec 2023 | -1.91M | 0 | 2.32M |
| Mar 2024 | -4.64M | 0 | 2.17M |
Seelos Therapeutics alternative data
| Aug 2023 | 16 |
|---|---|
| Sep 2023 | 16 |
| Oct 2023 | 16 |
| Nov 2023 | 16 |
| Dec 2023 | 16 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Apr 2024 | 15 |
| May 2024 | 15 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
Seelos Therapeutics other data
24.09%
-5.58%
of SEEL is owned by hedge funds
25.55M
-5.75M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 83000 | 0 |
| Dec 2023 | 151514 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MEHRA RAJ director, officer.. | Common Stock | 75,757 | $1.32 | $99,999 | ||
Purchase | MEHRA RAJ director, officer.. | Common Stock Warrant (right to buy) | 75,757 | $1.32 | $99,999 | ||
Purchase | GOLEMBIEWSKI MICHAEL JOSEPH officer: Chief Financial Officer | Common Stock | 83,000 | $1.21 | $100,264 | ||
Purchase | O'CONNOR DANIEL J. director | Common Stock | 16,000 | $0.61 | $9,792 | ||
Purchase | DALESANDRO MARGARET director | Common Stock | 35,000 | $0.6 | $20,965 | ||
Purchase | MEHRA RAJ director, officer.. | Common Stock | 66,667 | $0.85 | $56,867 | ||
Purchase | MEHRA RAJ director, 10 perc.. | Common Stock | 133,333 | $0.75 | $100,000 | ||
Option | DORSEY BRIAN other: Former SVP, Chief Dev Of.. | Common Stock | 81,775 | N/A | N/A | ||
Purchase | DENNER ALEXANDER J 10 percent owner | Warrants to purchase Common Stock | 2,835 | $8.8 | $24,948 | ||
Purchase | DENNER ALEXANDER J 10 percent owner | Common Stock | 6,104 | $1.63 | $9,950 |
| Patent |
|---|
Application TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE Filling date: 23 Jun 2021 Issue date: 21 Apr 2022 |
Application Filling date: 15 Jul 2020 Issue date: 14 Jan 2021 |
Grant Utility: Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose Filling date: 2 Jul 2019 Issue date: 22 Dec 2020 |
Grant Filling date: 31 Jan 2019 Issue date: 25 Aug 2020 |
Application TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE Filling date: 2 Jul 2019 Issue date: 12 Dec 2019 |
Grant Utility: Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose Filling date: 7 May 2014 Issue date: 3 Dec 2019 |
Application Filling date: 31 Jan 2019 Issue date: 7 Nov 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2017 2 Mar 2018 | Q4 2017 Earnings Call Transcript |
| Q3 2017 5 Nov 2017 | Q3 2017 Earnings Call Transcript |
| Q2 2017 3 Aug 2017 | Q2 2017 Earnings Call Transcript |
| Q1 2017 12 May 2017 | Q1 2017 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Raj Mehra J.D., Ph.D. (1960) Founder, Chairman, Chief Executive Officer & Pres | $724,230 |
-
When is Seelos Therapeutics's next earnings date?
Unfortunately, Seelos Therapeutics's (SEEL) next earnings date is currently unknown.
-
Does Seelos Therapeutics pay dividends?
No, Seelos Therapeutics does not pay dividends.
-
How much money does Seelos Therapeutics make?
Seelos Therapeutics has a market capitalization of 214.97K. Seelos Therapeutics made a loss 37.88M US dollars in net income (profit) last year or -$0.17 on an earnings per share basis.
-
What is Seelos Therapeutics's stock symbol?
Seelos Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SEEL".
-
What is Seelos Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Seelos Therapeutics?
Shares of Seelos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Seelos Therapeutics's key executives?
Seelos Therapeutics's management team includes the following people:
- Dr. Raj Mehra J.D., Ph.D. Founder, Chairman, Chief Executive Officer & Pres(age: 65, pay: $724,230)
-
Is Seelos Therapeutics founder-led company?
Yes, Seelos Therapeutics is a company led by its founder Dr. Raj Mehra J.D., Ph.D..
-
How many employees does Seelos Therapeutics have?
As Jul 2024, Seelos Therapeutics employs 10 workers, which is 33% less then previous quarter.
-
When Seelos Therapeutics went public?
Seelos Therapeutics, Inc. is publicly traded company for more then 26 years since IPO on 19 Apr 1999.
-
What is Seelos Therapeutics's official website?
The official website for Seelos Therapeutics is seelostherapeutics.com.
-
Where are Seelos Therapeutics's headquarters?
Seelos Therapeutics is headquartered at 300 Park Avenue, New York, NY.
-
How can i contact Seelos Therapeutics?
Seelos Therapeutics's mailing address is 300 Park Avenue, New York, NY and company can be reached via phone at +64 6 293 2100.
Seelos Therapeutics company profile:
Seelos Therapeutics, Inc.
seelostherapeutics.comExchange:
NASDAQ
Full time employees:
8
Industry:
Biotechnology
Sector:
Healthcare
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
300 Park Avenue
New York, NY 10022
New York, NY 10022
CIK: 0001017491
ISIN: US81577F2083
CUSIP: 81577F109
